How India Exports Sirolimus to the World

Sirolimus, marketed under the brand name Rapamune, received FDA approval in September 1999 for the prophylaxis of organ rejection in kidney transplant patients. In May 2015, the FDA expanded its approval to include the treatment of lymphangioleiomyomatosis (LAM), a rare lung disease. According to the FDA's Orange Book, multiple Abbreviated New Drug Applications (ANDAs) for generic sirolimus have been approved, indicating a competitive market landscape.

The substantial export of sirolimus from India to the United States, accounting for 97.5% of total exports, underscores the significance of the U.S. market for Indian manufacturers. With 97 active Indian exporters and a repeat buyer rate of 60.9%, the data reflects a robust and consistent demand. The average Free on Board (FOB) unit price of $9.57 suggests competitive pricing strategies among exporters.

In the European Union, sirolimus is authorized under the brand name Rapamune for preventing organ rejection in kidney transplant patients. The European Medicines Agency (EMA) granted this authorization in March 2001. Additionally, in May 2023, the EMA approved Hyftor, a sirolimus-based product, for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and pediatric patients aged six years and older. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with Good Manufacturing Practice (GMP) guidelines for sirolimus production. Manufacturers exporting to the EU and UK must adhere to these stringent quality and safety standards to ensure market access.

Sirolimus is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in healthcare systems worldwide. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, sirolimus is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for sirolimus, allowing market-driven pricing. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with regulatory standards.

The primary patents for sirolimus have expired, leading to increased generic competition. This has resulted in a diversified market with multiple manufacturers producing generic versions, contributing to the competitive pricing observed in export data.

In March 2025, TriviumVet DAC withdrew its application for Sirolimus TriviumVet, intended for managing hypertrophic cardiomyopathy in cats, during the EMA's assessment process. The withdrawal was due to the Committee for Medicinal Products for Veterinary Use (CVMP) concluding that the data provided did not support a positive benefit-risk balance. (ema.europa.eu)

In May 2023, the EMA approved Hyftor, a sirolimus-based topical treatment for facial angiofibroma associated with tuberous sclerosis complex, expanding the therapeutic applications of sirolimus within the EU. (ema.europa.eu)

These developments reflect the dynamic regulatory landscape surrounding sirolimus, with ongoing evaluations and approvals influencing its market presence and therapeutic applications.

Sirolimus, an immunosuppressant used primarily to prevent organ transplant rejection, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency poses a significant risk, as any disruption in the supply of these KSMs can halt API production, leading to potential shortages of the final drug. The U.S. Pharmacopeia reported in October 2025 that 41% of KSMs used for U.S.-approved APIs are solely sourced from China, highlighting the vulnerability of the supply chain.

Recent disruptions have underscored this risk. In February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), including quality control failures and data integrity issues. Such regulatory actions can lead to production halts and supply chain interruptions, emphasizing the need for diversified sourcing strategies.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in the export of Sirolimus from India. The top five exporters account for 91.2% of the total export value, with Zydus Lifesciences Limited alone contributing 37.5%. This concentration increases the risk of supply disruptions, as issues affecting these key suppliers can have a disproportionate impact on the global availability of Sirolimus.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing of critical APIs and reduce import dependency. As of December 2025, the scheme has led to the creation of manufacturing capacities for 26 KSMs and APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. While this initiative is a positive step, its focus on specific products means that Sirolimus may not directly benefit, leaving its supply chain vulnerabilities unaddressed.

Geopolitical tensions and shipping disruptions pose additional risks to the Sirolimus supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical exports. Any instability in these regions can lead to delays and increased shipping costs. Furthermore, escalating U.S.-China tensions have the potential to disrupt the supply of KSMs from China, directly impacting API production in India.

Regulatory bodies have also highlighted these concerns. In October 2025, the FDA noted that 58% of KSMs used for U.S.-approved APIs are sourced from a single country, with 41% from China, emphasizing the need for supply chain diversification to mitigate potential disruptions.

• Diversify KSM Sourcing: Identify and qualify alternative suppliers for KSMs to reduce dependency on a single country, particularly China.

• Enhance Supplier Audits: Implement rigorous and regular audits of API manufacturers to ensure compliance with cGMP and mitigate quality-related disruptions.

• Invest in Domestic Production: Encourage investment in domestic manufacturing of critical KSMs and APIs through incentives and support, reducing reliance on imports.

• Develop Contingency Plans: Establish comprehensive contingency plans to address potential geopolitical and shipping disruptions, ensuring continuity of supply.

• Monitor Regulatory Developments: Stay informed about regulatory changes and potential sanctions that could impact the supply chain, allowing for proactive adjustments.

RISK_LEVEL: HIGH